Most investors ignore sectors until the first major regulatory approvals arrive. By then, much of the upside may already be reflected in valuations. Early-stage biotech carries significant risk, but that’s often where asymmetric returns are found.
NFA.
I think psychedelic medicine could be one of the biggest biotech investment opportunities of the next decade. If clinical trials continue to deliver and regulators approve these therapies, $CMPS, $ATAI, $GHRS and $CYBN could be among the biggest beneficiaries.
NFA.
Every major investment theme starts out looking improbable. AI, mRNA and GLP-1s all had sceptics. Psychedelic medicine may follow a similar path if therapies based on psilocybin and DMT continue to prove safe and effective in clinical trials.
NFA.
The science is what caught my attention. We’re seeing growing evidence in treatment-resistant depression, PTSD and addiction, with multiple companies now in late-stage clinical trials. High risk? Absolutely. But the upside could be transformative if even a few succeed.
NFA.
Bored of crap finance 'guru's' on here tweeting shit. Instead of buying bottled water, I collected rain water, and invested that £1.50 into my S&S ISA! Compound Growth📈📊